Statins: The Dispensing Safety Checklist

📋 First Dispense Essentials

Mandatory items to issue

• Patient information leaflet supplied with the medicine. Confirm patient has received it.
• Verbal counselling on muscle symptoms: patients must report unexplained muscle pain, weakness, or tenderness, particularly if accompanied by dark urine. Very rarely, statins have been associated with new or worsening myasthenia gravis symptoms: report new double vision, drooping eyelids, difficulty swallowing, or worsening muscle weakness.
• Advise on grapefruit: large amounts of grapefruit or grapefruit juice can raise simvastatin and atorvastatin levels to a clinically significant degree. Rosuvastatin and pravastatin are not clinically significantly affected.

Baseline clinical checks

• Liver transaminases (ALT or AST) before starting. Statins are generally avoided in active liver disease.
• Full lipid profile at baseline. Fasting is not required in all cases; follow local guidance or clinical context.
• Full lipid profile and liver transaminases at 2 to 3 months after starting or changing lipid-lowering treatment. Liver transaminases again at 12 months. Further testing is only needed if clinically indicated thereafter.
• Creatine kinase (CK) at baseline if the patient has risk factors for myopathy: older age, hypothyroidism, renal impairment, personal or family history of muscle disorders, or high alcohol intake.
• Thyroid function: untreated hypothyroidism increases the risk of statin-related myopathy. Confirm thyroid function has been checked if relevant.
• Confirm the patient is not pregnant, planning pregnancy, suspects pregnancy, or breastfeeding.

Key risks and lifestyle traps

• Simvastatin dose caps: simvastatin must not exceed 20 mg daily when used with amlodipine or diltiazem. With amiodarone or verapamil the same 20 mg cap applies. Gemfibrozil, ciclosporin, and danazol are contraindicated with simvastatin due to severe myopathy risk.
• Macrolide antibiotics: clarithromycin and erythromycin can substantially increase simvastatin and atorvastatin exposure. Avoid the combination where possible. If clarithromycin or erythromycin is essential, check whether simvastatin or atorvastatin should be temporarily withheld during the antibiotic course and seek prescriber advice. Azithromycin has much lower interaction potential and can usually be used with statins, but counsel patients to report any unexplained muscle symptoms.
• Systemic fusidic acid must not be used with statins. If systemic fusidic acid is essential, the statin should be discontinued during the course under prescriber advice. The statin should normally not be restarted until at least 7 days after the last fusidic acid dose, unless specialist advice indicates otherwise.
• Azole antifungals: itraconazole, ketoconazole, and posaconazole are strong CYP3A4 inhibitors and markedly increase simvastatin and atorvastatin exposure. Fluconazole is less potent but still interaction-relevant. These combinations require review or an alternative antifungal.
• HIV antivirals, hepatitis C antivirals, and colchicine can increase statin exposure and myopathy risk. These combinations require review before dispensing.
• Ciclosporin and tacrolimus can increase statin exposure. These combinations require specialist oversight.
• Fibrates: use with statins increases myopathy risk; gemfibrozil is contraindicated with most statins. Fenofibrate may be used with caution under specialist guidance.
• Grapefruit juice in large amounts can raise simvastatin and atorvastatin levels. Rosuvastatin and pravastatin are not clinically significantly affected.
• Warfarin: statins, particularly fluvastatin and rosuvastatin, may increase anticoagulant effect. Check that International Normalised Ratio (INR) monitoring is up to date if the patient is taking warfarin.
• Statin intolerance: do not advise the patient to permanently stop or switch statins without prescriber review, unless red-flag symptoms (such as suspected rhabdomyolysis) require urgent assessment.
• St John's wort and some herbal preparations can affect statin metabolism. Always check over-the-counter and herbal medicines.
• Pregnancy and breastfeeding: statins should be stopped if pregnancy is a possibility, stopped at least 3 months before attempting conception, and not restarted until breastfeeding has finished. If the patient is pregnant, planning pregnancy, or suspects pregnancy, refer promptly to the prescriber.
• Alcohol: regular heavy alcohol intake increases the risk of liver toxicity. Advise moderation.

First dispense script

🔄 Repeat Dispense Screen

Mandatory documentation

• Record the date of the last liver transaminase result on the dispensing record. Flag if overdue.
• Note any dose changes from the previous prescription, particularly for simvastatin (dose caps apply with several common medicines). Check dose strength carefully after statin switches, for example atorvastatin to rosuvastatin or simvastatin to atorvastatin.
• Document any new interacting medicines added since the last dispense, including hospital discharge medicines and recent acute prescriptions.

Ongoing clinical checks

• Full lipid profile and liver transaminases: at 2 to 3 months after starting or changing lipid-lowering treatment. Liver transaminases again at 12 months. Further testing only if clinically indicated.
• Creatine kinase (CK): only if the patient reports muscle symptoms. Routine CK monitoring is not recommended in patients without symptoms.
• In patients taking warfarin: confirm International Normalised Ratio (INR) monitoring has been reviewed after any statin dose change or statin switch.

Ask the patient at the counter

• "Have you had any unexplained muscle pain, weakness, or tenderness since your last prescription? Any dark or brown urine?"
• "Have you started any new medicines, including antibiotics, antifungals, medicines from a hospital clinic, herbal remedies, or supplements?"

Lifestyle and surgical alerts

• New or increased exercise: intensive or unfamiliar exercise alongside statin treatment can increase the risk of muscle injury. Advise patients to increase activity gradually and report unusual muscle symptoms.
• Pregnancy, planning pregnancy, or breastfeeding: statins should be stopped and the prescriber contacted promptly.
• Alcohol: consistent moderate intake is preferable. Heavy or binge drinking increases the risk of liver toxicity.
• Grapefruit: patients taking simvastatin or atorvastatin should avoid large or regular amounts of grapefruit or grapefruit juice.

Download the checklist